The corona vaccine manufacturer Biontech presents its balance sheet for the third quarter – and gives an overview of new developments.
Profits and sales at the corona vaccine manufacturer Biontech are no longer growing as quickly as before. In the third quarter, the Mainz-based company generated a net profit of around 1.8 billion euros, compared to 3.2 billion in the same period last year, as Biontech announced.
Sales fell from almost 6.1 billion euros in the third quarter of 2021 to just under 3.5 billion euros. The company referred to the development of the corona pandemic, which led to fluctuations in quarterly sales.
Together with US partner Pfizer, Biontech is currently expanding its leading position in several countries and regions of the world with the market launch of the vaccine adapted to the current Omicron subvariants BA.4/5.
Biontech raised the sales forecast for its corona vaccine for the current fiscal year and now narrowed it down to a range of 16 to 17 billion euros to the upper end of the original range of 13 billion to 17 billion euros.
Source: Stern
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
